Objective:This study was conducted to examine the effect of focal adhesion kinase-associated non-kinase(FRNK)overexpression or inhibition on hepatic stellate cell(HSC)-mediated liver fibrosis progression and to explor...Objective:This study was conducted to examine the effect of focal adhesion kinase-associated non-kinase(FRNK)overexpression or inhibition on hepatic stellate cell(HSC)-mediated liver fibrosis progression and to explore the role of FRNK in improving liver fibrosis.Methods:i)Using primary mouse HSCs and the human HSC cell line LX-2.展开更多
Focal adhesion kinase （FAK） and proline-rich tyrosine kinase 2 （Pyk2） are non-receptor protein tyrosine kinases that are involved in cell proliferation, migration and survival. Current research of FAK and Pyk2 is ...Focal adhesion kinase （FAK） and proline-rich tyrosine kinase 2 （Pyk2） are non-receptor protein tyrosine kinases that are involved in cell proliferation, migration and survival. Current research of FAK and Pyk2 is greatly focused in cancer biology and several small molecule inhibitors are being tested under clinical development. Like cancer, certain chronic diseases such as cardiovascular disease, bone disease, fibrosis, rheumatoid arthritis, and neurological disorders, share malignant characteristics of cancer. Accumulating evidence has demonstrated that FAK and Pyk2 contribute to other proliferative and degenerative diseases. Thus, the goal of this review is to briefly highlight studies that have implicated FAK and Pyk2 as players in disease progression.展开更多
文摘Objective:This study was conducted to examine the effect of focal adhesion kinase-associated non-kinase(FRNK)overexpression or inhibition on hepatic stellate cell(HSC)-mediated liver fibrosis progression and to explore the role of FRNK in improving liver fibrosis.Methods:i)Using primary mouse HSCs and the human HSC cell line LX-2.
文摘Focal adhesion kinase （FAK） and proline-rich tyrosine kinase 2 （Pyk2） are non-receptor protein tyrosine kinases that are involved in cell proliferation, migration and survival. Current research of FAK and Pyk2 is greatly focused in cancer biology and several small molecule inhibitors are being tested under clinical development. Like cancer, certain chronic diseases such as cardiovascular disease, bone disease, fibrosis, rheumatoid arthritis, and neurological disorders, share malignant characteristics of cancer. Accumulating evidence has demonstrated that FAK and Pyk2 contribute to other proliferative and degenerative diseases. Thus, the goal of this review is to briefly highlight studies that have implicated FAK and Pyk2 as players in disease progression.
